SRHQ - ETF AI Analysis
Top Page
SRH U.S. Quality ETF (SRHQ)
SRHQ, the SRH U.S. Quality ETF, earns a solid overall rating thanks to several strong holdings like Qualys, Abercrombie & Fitch, and Frontdoor, which show robust financial performance, healthy profitability, and positive earnings outlooks that support the fund’s quality focus. However, positions such as Centene and Insperity, which face profitability and valuation challenges, modestly weigh on the rating, and there is some risk from holdings with bearish technical trends or high leverage that could add volatility.
SRHQ vs. SPDR S&P 500 ETF (SPY)
- AUM
- 219.73M
- Region
- North America
- Expense Ratio
- 0.35%
- Beta
- 0.81
- Issuer
- SRH
- Inception Date
- Oct 05, 2022
- Dividend Yield
- 0.69%
- Asset Class
- Equity
- Index Tracked
- SRH U.S. Quality GARP Index - Benchmark TR Gross
SRHQ Summary
SRH U.S. Quality ETF (SRHQ) is a U.S. stock fund that follows the SRH U.S. Quality GARP Index, focusing on large, financially strong companies. It mainly invests in U.S. businesses across technology, health care, and industrials, aiming for steady growth from well-run firms. Some recognizable names in the fund include Humana and Abercrombie & Fitch. An investor might choose SRHQ for diversified exposure to high-quality U.S. companies in one simple investment. However, like any stock-focused ETF, its value can go up or down with the overall stock market.
How much will it cost me?
SRHQ has an annual expense ratio of 0.35%, which means you’ll pay about $3.50 per year for every $1,000 you invest. This cost is a bit higher than many broad, passively managed index ETFs because SRHQ is actively managed with a specialized focus on high-quality U.S. large-cap companies.
What would affect this ETF?
SRHQ could benefit if the U.S. economy stays healthy and large, high-quality companies in technology, health care, and industrials continue to grow, as its focus on strong balance sheets may help it hold up better during market swings. On the downside, a U.S. slowdown, higher interest rates, or sector-specific challenges in areas like health care regulation or tech competition could weigh on its mainly U.S.-based holdings and reduce returns.
SRHQ Top 10 Holdings
SRHQ leans heavily into U.S. tech and health care, with names like Qualys, Box, Nutanix, and Dropbox quietly steering the ship. Qualys and Box have been rising, giving the fund a lift as cybersecurity and cloud software stay in favor, while Nutanix and Dropbox look more mixed, with momentum cooling and valuation worries holding them back. On the health care side, Humana and Centene are steady contributors, though ongoing profitability questions keep them from truly breaking out. Overall, it’s a U.S.-centric, quality-focused portfolio with a clear tilt toward digital infrastructure and medical services.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 QLYS | Qualys | 2.79% | $6.22M | $7.97B | 87.90% | 78Outperform |
 HUM | Humana | 2.56% | $5.72M | $50.14B | 42.67% | 69Neutral |
 CVLT | CommVault Systems | 2.35% | $5.23M | $7.02B | 22.46% | 65Neutral |
 CNC | Centene | 2.23% | $4.98M | $33.97B | 83.77% | 58Neutral |
 NTNX | Nutanix | 1.98% | $4.42M | $19.28B | 3.77% | 62Neutral |
 NSP | Insperity | 1.82% | $4.06M | $1.77B | 8.92% | 54Neutral |
 BOX | Box | 1.95% | $4.35M | $5.95B | 36.85% | 65Neutral |
 ANF | Abercrombie Fitch | 1.93% | $4.31M | $7.03B | 126.25% | 78Outperform |
 AMRX | Amneal Pharmaceuticals | 1.83% | $4.08M | $6.82B | 104.70% | 58Neutral |
 DBX | Dropbox | 1.70% | $3.79M | $7.89B | 27.82% | 62Neutral |
SRHQ Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For SRHQ, the sentiment is Positive. The current price of 50.02 is above the 20-day moving average (MA) of 48.59, above the 50-day MA of 48.53, and above the 200-day MA of 44.76, indicating a bullish trend. The MACD of 0.52 indicates Negative momentum. The RSI at 63.41 is Neutral, neither overbought nor oversold. The STOCH value of 60.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SRHQ.
SRHQ Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| SRHQ | $50.02 | $52.00(3.96% Upside) | $219.73M | 0.35% | 70Neutral |
 INFO | $28.26 | $34.24(21.18% Upside) | $962.79M | 0.35% | 74Outperform |
 AFLG | $44.92 | $53.36(18.79% Upside) | $931.04M | 0.55% | 74Outperform |
 XVV | $58.78 | $71.62(21.85% Upside) | $902.10M | 0.08% | 74Outperform |
 PTL | $275.30 | $342.81(24.52% Upside) | $886.88M | 0.09% | 70Neutral |
 ROCY | $55.36 | $66.94(20.93% Upside) | $886.34M | 0.35% | 73Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SRHQ | SRH U.S. Quality ETF | 50.02 | 11.39 | 29.48% | |
| INFO | Harbor PanAgora Dynamic Large Cap Core ETF | 28.25 | 3.86 | 15.83% | |
| AFLG | First Trust Active Factor Large Cap ETF | 44.92 | 6.13 | 15.81% | |
| XVV | iShares ESG Screened S&P 500 ETF | 58.78 | 6.53 | 12.51% | |
| PTL | Inspire 500 ETF | 275.30 | 25.79 | 10.33% | |
| ROCY | JPMorgan Equity Premium Yield ETF | 55.36 | 7.32 | 15.23% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.